Advisory Services Network Lowers stake in United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : Advisory Services Network reduced its stake in United Therapeutics Corporation by 10.23% during the most recent quarter end. The investment management company now holds a total of 1,185 shares of United Therapeutics Corporation which is valued at $146,371 after selling 135 shares in United Therapeutics Corporation , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.United Therapeutics Corporation makes up approximately 0.03% of Advisory Services Network’s portfolio.

Other Hedge Funds, Including , Independent Portfolio Consultants reduced its stake in UTHR by selling 10 shares or 5.71% in the most recent quarter. The Hedge Fund company now holds 165 shares of UTHR which is valued at $20,041. United Therapeutics Corporation makes up approx 0.01% of Independent Portfolio Consultants’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in UTHR by selling 77,715 shares or 88.64% in the most recent quarter. The Hedge Fund company now holds 9,962 shares of UTHR which is valued at $1,209,985. Eqis Capital Management sold out all of its stake in UTHR during the most recent quarter. The investment firm sold 2,394 shares of UTHR which is valued $290,775. Washington Trust Bank added UTHR to its portfolio by purchasing 6 company shares during the most recent quarter which is valued at $729.

United Therapeutics Corporation opened for trading at $121.14 and hit $123.74 on the upside on Friday, eventually ending the session at $123.52, with a gain of 1.90% or 2.3 points. The heightened volatility saw the trading volume jump to 4,87,464 shares. Company has a market cap of $5,369 M.

On the company’s financial health, United Therapeutics Corporation reported $4.55 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $3.52. The company had revenue of $412.60 million for the quarter, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.